somatotroph is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Propranolol is classified as a competitive non-cardioselective sympatholytic beta blocker that crosses the blood–brain barrier. It is lipid soluble and also has sodium channel-blocking effects. Propranolol is a non-selective β-adrenergic receptor antagonist, or beta blocker; that is, it blocks the action of epinephrine (adrenaline) and norepinephrine (noradrenaline) at both β1- and β2-adrenergic receptors. It has little intrinsic sympathomimetic activity, but has strong membrane stabilizing activity (only at high blood concentrations, e.g. overdose). Propranolol can cross the blood–brain barrier and exert effects in the central nervous system in addition to its peripheral activity. In addition to blockade of adrenergic receptors, propranolol has very weak inhibitory effects on the norepinephrine transporter and/or weakly stimulates norepinephrine release (i.e., the concentration of norepinephrine is increased in the synapse). Since propranolol blocks β-adrenoceptors, the increase in synaptic norepinephrine only results in α-adrenoceptor activation, with the α1-adrenoceptor being particularly important for effects observed in animal models. Therefore, it can be looked upon as a weak indirect α1-adrenoceptor agonist in addition to potent β-adrenoceptor antagonist. In addition to its effects on the adrenergic system, there is evidence that indicates that propranolol may act as a relatively weak antagonist of certain serotonin receptors, namely the 5-HT1A, 5-HT1B, and 5-HT2B receptors.
The editors of Detlev Peukert und die NS-Forschung, Rüdiger Hachtmann and Sven Reichardt, argued that Peukert was one of the most important historians on the Nazi era as he shifted research from the subject of Verführung und Gewalt (Seduction and Violence) to Volksgenossen und Gemeinschaftsfremde (National Comrades and Community Aliens) focusing on "the role of ordinary people, as insiders (believers, conformers, bystanders) in their relation to perceived outsiders." One of the contributors to Detlev Peukert und die NS-Forschung, Nikolaus Wachsmann, argued that Peukert's focus on looking at all groups victimized by the Nazi regime as Gemeinschaftsfremde (Community Aliens) such as the Romany, homosexuals, and the disabled missed the centrality of völkisch anti-Semitic ideology to the "Final Solution of the Jewish Question". Wachsmann further noted that a central problem with Peukert's work was it was entirely concerned with Germany and he missed that the majority of the people killed by the Nazi regime were in Eastern Europe. Waschsman criticized Peukert for failing to go beyond his own point that the violence of the Nazi regime tended to be directed against people considered to be "outsiders" in Germany which meant the vast majority of the victims of Nazi violence were people in Eastern Europe, observing that Peukert had little to say about the extermination of Eastern European Jews, the sheer brutality of German policies in Poland or the mass murder of three million Red Army POWs in 1941–42 as all this happened outside of Germany.
Serology for hepatitis viruses, autoantibodies (ANA, anti-smooth muscle, antimitochondria, anti-LKM) Ferritin and transferrin saturation: markers of iron overload as in hemochromatosis, copper and ceruloplasmin: markers of copper overload as in Wilson's disease Immunoglobulin levels (IgG, IgM, IgA) – these immunoglobulins are nonspecific, but may help in distinguishing various causes. IgG level is elevated in chronic hepatitis, alcoholic hepatitis, and autoimmune hepatitis. It is a slow and sustained increase is seen in viral hepatitis. IgM significantly increased in primary biliary cirrhosis and moderately increased in viral hepatitis and cirrhosis. IgA is increased in alcoholic cirrhosis and primary biliary cirrhosis. Cholesterol and glucose Alpha 1-antitrypsin Markers of inflammation and immune cell activation are typically elevated in cirrhotic patients, especially in the decompensated disease stage:
Thaumatin (also known as talin) is a low-calorie sweetener and taste modifier. The protein is often used primarily for its flavor-modifying properties and not exclusively as a sweetener. The thaumatins were first found as a mixture of proteins isolated from the katemfe fruit (Thaumatococcus daniellii) (Marantaceae) of West Africa. Although very sweet, thaumatin's taste is markedly different from sugar's. The sweetness of thaumatin builds very slowly. Perception lasts a long time, leaving a liquorice-like aftertaste at high concentrations. Thaumatin is highly water soluble, stable to heating, and stable under acidic conditions.
Sources: en.wikipedia.org
== Synthesis == SRTXs are abundant in venoms, whereas ETs are present in a low concentration in mammals. Both ETs and SRTXs are generated in vivo by proteolytic cleavage from larger precursors. They also can be produced by solid phase peptide synthesis and fold spontaneously in vitro in high yield into native tertiary structures, with the correct disulfide bond pairing of cysteines. SRTXs complete cDNA sequence comprises 1948 base pairs (bp) coding for a pre-pro-polypeptide of 543 amino acids, which starts with a methionine that initiates translation followed by a hydrophobic peptide characteristic of a signal sequence. The amino acid sequence comprises one sequence of 39 amino acidic residues followed by 11 sequences of 40 residues, each of it contains one SRTX sequence preceded by 19 spacer amino acids. The SRTX-c isoform is the most abundant in the venom and is also the isoform with the greatest number of copies (five in all) in the precursor.
The swim bladder is attached to the fish's spine, and is removed during processing. High value fish maw is typically removed and dried onboard fishing vessels when conditions allow. Established commercial fishing industries worldwide sell swim bladders as by-product to fish maw importers. In 2018, the Norwegian fishing industry supplied over 25% of the world fish maw market share, largely with codfish, followed by Russia at 14.9%. Other prominent exporters in the Chinese fish maw import market include Iceland, which exports cod and true ling, and New Zealand, which exports Genypterus blacodes or New Zealand ling. The Chinese demand for wild-caught fish maw, particularly from exotic foreign fish, has increased significantly since the reform and opening up of China. The greatest determiner of value is the origin species. Sciaenidae (croakers or drums) maw demands the highest price, for its perceived superior quality over other species. The average price per kilogram for fish maw is 72 times higher than the price of flesh, and can reach over 8000 times higher in extreme circumstances like the totoaba trade; in these cases, the rest of the fish becomes byproduct, and is often discarded.
=== Dentinal sclerosis === Dentinal sclerosis or transparent dentin sclerosis of primary dentin is a change in the structure of teeth characterized by calcification of dentinal tubules. It can occur as a result of injury to dentin by caries or abrasion, or as part of the normal aging process.
Sexual dysfunction, including loss of libido, erectile dysfunction, lack of vaginal lubrication, and anorgasmia, are some of the most commonly encountered adverse effects of treatment with fluoxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is >70%. In 2019, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that packaging leaflets of selected SSRIs and SNRIs should be amended to include information regarding a possible risk of persistent sexual dysfunction. Following on the European assessment, a safety review by Health Canada "could neither confirm nor rule out a causal link ... which was long lasting in rare cases", but recommended that "healthcare professionals inform patients about the potential risk of long-lasting sexual dysfunction despite discontinuation of treatment".
6 July – BBC News reports that Reform UK would be highly unlikely to introduce an insurance based healthcare system in Wales should it win the 2026 Senedd election, largely because of the timescale and potential legal implications of doing so. 7 July – David Jones, a former Conservative Secretary of State for Wales who stepped down from Parliament at the 2024 election, announces he is defecting to Reform UK. Amazon removes a number of AI-generated unofficial biographies of Scotland's first ministers from sale after BBC News alerts them to a significant number of inaccuracies contained within the books. 8 July – French President Emmanuel Macron begins a three-day state visit to the UK, becoming the first French President to visit the UK since 2008, and the first European leader to do so since Brexit. Former prime minister Rishi Sunak joins Goldman Sachs as a senior advisor. James McMurdock says he will not return to Reform UK after asking to have the party whip withdrawn. Sir Robert Chote resigns as chairman of the UK Statistics Authority, the body that oversees the Office for National Statistics. MPs vote 415–98 to approve the Football Governance Bill that will establish a regulatory body for the top five tiers of English football. 9 July – Secretary of State for Wales Jo Stevens says public services in Wales will not face cuts despite a shortfall in covering a rise in employers' National Insurance contributions. Her comments follow a warning from Welsh Government Finance Secretary Mark Drakeford, who warned Wales was facing a £36m financial black hole.
Sources: en.wikipedia.org
As of September 11, 2017, Teva remained the "world's biggest seller of generics medicines." On September 11, 2017, it was reported that they had selected Kåre Schultz as the new Teva CEO. A day later the company announced it would sell its Paragard contraceptive brand to Cooper Cos for $1.1 billion, with the funds being used to pay down debt. Days later the company announced further divestments: a sale of contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million and its emergency contraception brands for $675 million to Foundation Consumer Healthcare. By December, the company had announced a drastic 25 percent workforce reduction (greater than 14,000 employees) as part of a two-year cost-reduction strategy. Following considerable lobbying by the Israeli Government, from whom Teva received considerable tax breaks, and from Israel's labor federation, the Histadrut, Teva agreed to delay some of the layoffs in Israel. In October 2019, Teva faced criticism for making a "business decision to discontinue the drug" Vincristine, essential for the treatment of most childhood cancers according to the Food and Drug Administration.
compared phenotypic defects observed in zebrafish treated with silver nanoparticles and silver ions and determined that the phenotypic defects observed with silver nanoparticle treatment was not observed with silver ion-treated embryos, suggesting that the toxicity of silver nanoparticles is independent of silver ions. Protein channels and nuclear membrane pores can often be in the size range of 9 nm to 10 nm in diameter. Small silver nanoparticles constructed of this size have the ability to not only pass through the membrane to interact with internal structures but also to become lodged within the membrane. Silver nanoparticle depositions in the membrane can impact regulation of solutes, exchange of proteins and cell recognition. Exposure to silver nanoparticles has been associated with "inflammatory, oxidative, genotoxic, and cytotoxic consequences"; the silver particulates primarily accumulate in the liver. but have also been shown to be toxic in other organs including the brain. Nano-silver applied to tissue-cultured human cells leads to the formation of free radicals, raising concerns of potential health risks.
In January 2022, the business announced it would acquire Affera, Inc. In March, Medtronic announced a contract with Vizient, a healthcare performance improvement company, to add Medtronic's Touch Surgery Enterprise platform to Vizient's healthcare offerings. Touch Surgery works with laparoscopic and robotic scopes and is an AI-powered video management and analytics platform for the operating room. In May, Medtronic and DaVita Inc. announced plans to form a new, independent kidney care-focused medical device company. Medtronic's Renal Care Solutions business will be part of the new company. In April 2022, the company announced a collaboration with GE Healthcare to support the needs and care demands at Ambulatory Surgery Centers. In July, Medtronic announced a strategic partnership with CathWorks, a coronary artery disease (CAD) technology developer. A separate agreement gave Medtronic the option to acquire CathWorks in the future. In October 2022, the company announced its intention to pursue a separation of the company's combined Patient Monitoring and Respiratory Interventions businesses, which are part of the company's Medical Surgical Portfolio. In February 2024, the company announced that it had reversed its decision to spin off or sell the Patient Monitoring and Respiratory Interventions businesses, and would instead combine them into a new business unit called Acute Care & Monitoring. They also announced that they would discontinue the ventilator product line, citing its unprofitability.
=== Ehlers–Danlos syndrome hypermobility type === Joint hypermobility is often correlated with hypermobile Ehlers–Danlos syndrome (hEDS, known also by EDS type III or Ehlers–Danlos syndrome hypermobility type (EDS-HT)). Ehlers–Danlos syndrome is a genetic disorder caused by mutations or hereditary genes, but the genetic defect that produces hEDS is largely unknown. In conjunction with joint hypermobility, a common symptom for hEDS is smooth, velvety, and stretchy skin. When diagnosing hEDS, the Beighton Criteria are used, but are not always able to distinguish between joint hypermobility syndrome and hEDS. Ehlers–Danlos hypermobility type can have severe musculoskeletal effects, including:
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.